Valuation Allogene Therapeutics, Inc.

Stocks

Market Closed - Nasdaq Other stock markets 16:00:00 2026-08-03 EDT			5-day change	1st Jan Change
1.840 ^USD	-2.13%		+5.14%	+34.31%

07-29	Allogene Therapeutics' Cemacabtagene Ansegedleucel Receives FDA RMAT, Fast Track Designations	MT
07-29	Allogene Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy And Fast Track Designations For Cemacabtagene Ansegedleucel As First-Line Consolidation Therapy For Large B-Cell Lymphoma	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	2,126	907.1	540.2	446.6	307.9	635.1	-	-
Change	-	-57.34%	-40.45%	-17.32%	-31.06%	106.28%	-	-
Enterprise Value (EV) ¹	1,317	330.6	91.47	234.8	347	449.4	534.3	529.1
Change	-	-74.89%	-72.33%	156.69%	47.8%	29.49%	18.89%	-0.97%
P/E	-7.89x	-2.71x	-1.54x	-1.61x	-1.57x	-2.59x	-2.41x	-2.58x
PBR	2.32x	1.36x	1.06x	1.07x	1.07x	1.64x	1.06x	1.38x
PEG	-	-0.1x	0.16x	0x	0x	0.1x	-0.32x	0.4x
Capitalization / Revenue	55.2x	3,733x	5,686x	20,300x	-	95,215x	43.5x	5.91x
EV / Revenue	34.2x	1,361x	963x	10,673x	-	67,376x	36.6x	4.92x
EV / EBITDA	-5.37x	-1.03x	-0.29x	-0.96x	-1.76x	-2.26x	-2.26x	-1.95x
EV / EBIT	-5.15x	-0.99x	-0.28x	-0.91x	-1.66x	-2.09x	-2.17x	-2.24x
EV / FCF	-6.38x	-1.46x	-0.38x	-1.17x	-2.32x	-2.88x	-3.12x	-3.96x
FCF Yield	-15.7%	-68.3%	-262%	-85.6%	-43.1%	-34.7%	-32.1%	-25.2%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	-1.89	-2.32	-2.09	-1.32	-0.87	-0.7095	-0.7627	-0.7129
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	38.49	0.243	0.095	0.022	-	0.00667	14.59	107.5
EBITDA ¹	-245.3	-321.2	-313.5	-243.8	-197	-198.7	-235.9	-271.5
EBIT ¹	-255.8	-335.4	-327.7	-257.5	-209.3	-214.7	-246.7	-236.6
Net income ¹	-257	-332.6	-327.3	-257.6	-190.9	-197.3	-231.1	-225.9
Net Debt ¹	-809.5	-576.5	-448.7	-211.8	39.16	-185.7	-100.8	-106
Reference price ²	14.920	6.290	3.210	2.130	1.370	1.840	1.840	1.840
Nbr of stocks (in thousands)	142,516	144,210	168,277	209,672	224,730	345,155	-	-
Announcement Date	2/23/22	2/28/23	3/14/24	3/13/25	3/12/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ALLOGENE THERAPEUTICS, INC.	-2.59x	67376.31x	-2.26x	-.--%	635M
WUXI APPTEC CO., LTD.	17.93x	5.93x	12.15x	1.71%	56.7B
ARGENX SE	30.64x	7.55x	23.21x	0.05%	51.97B
BIONTECH SE	-18.24x	4.35x	-7.62x	-.--%	23.33B
INSMED INCORPORATED	-37.99x	12.2x	-35.93x	-.--%	21.34B
GENMAB A/S	24.11x	4.7x	15.27x	-.--%	17.44B
PHARMAESSENTIA CORPORATION	44.73x	18.1x	46.61x	0.08%	14.77B
EXELIXIS, INC.	17.37x	5.01x	11.7x	-.--%	13.84B
ARROWHEAD PHARMACEUTICALS, INC.	-26.49x	25.4x	-31.82x	-.--%	12.12B
MADRIGAL PHARMACEUTICALS, INC.	-76.33x	6.97x	-57.58x	-.--%	11.14B
Average	-2.69x	6,746.65x	-2.63x	0.18%	22.33B
Weighted average by Cap.	6.82x	200.13x	4.65x	0.45%